Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial

oleh: Mitchell S Cairo, Stephan Voss, Qiuhu Shi, Jessica Hochberg, Jaclyn Basso, Liana Klejmont, Allyson Flower, Kristina Bortfeld, Lauren Harrison, Carmella van de Ven, Chitti Moorthy, Humayun Islam, Perry Gerard

Format: Article
Diterbitkan: BMJ Publishing Group 2022-05-01

Deskripsi

No description available for this item.